Inflammatory Bowel Disease (IBD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Inflammatory Bowel Disease (IBD) Market Outlook

Thelansis’s “Inflammatory Bowel Disease (IBD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Inflammatory Bowel Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Inflammatory Bowel Disease (IBD) Overview

Inflammatory bowel disease (IBD) is a chronic inflammatory condition affecting the gastrointestinal tract. It arises due to an abnormal immune response to gut microflora, resulting in recurrent episodes of inflammation. The two primary forms of IBD are Crohn's disease and ulcerative colitis (UC). IBD develops in genetically susceptible individuals when their immune system reacts inappropriately to the intestinal flora. Crohn's disease is characterized by segmental inflammation that affects the entire GI tract, often with granulomas. In contrast, UC primarily involves inflammation of the colon and rectal mucosa. These conditions are relatively common in pediatric patients, with a significant number diagnosed before age 20. Inflammatory bowel disease can also extend to the tracheobronchial tree, affecting the larynx, trachea, and both large and small airways, leading to airway inflammation. Large airway inflammation is the most frequent, occurring in approximately 40% of IBD patients. About 10% of patients may experience upper respiratory tract or small airway involvement. The primary distinction between Crohn's disease and ulcerative colitis lies in their anatomical distribution. Crohn's disease can impact any part of the gastrointestinal tract, although it is most common in the ileum and colon. It displays a segmental, non-continuous inflammation, often with transmural involvement. Complications such as deep-penetrating ulcerations, fistulas, and abscesses can occur. A distinctive histological feature is the presence of epithelioid granulomas. On the other hand, UC is confined to the colon and rectum, featuring continuous and diffuse mucosal inflammation that typically begins distally and progresses proximally.

• In the United States, an estimated 3.1 million adults (1.3% of the population) have been diagnosed with inflammatory bowel disease (comprising Crohn's disease and ulcerative colitis).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: